What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.35%Below 5Y avg (1.04%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
19.0%Sustainable
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.64BCNY
543.56M · vs all stocks (USD)
Updated Sep 20, 2026
Trailing P/E
55.82x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Revenue (TTM)
1.63BCNY
243.37M · vs all stocks (USD)
Updated Sep 20, 2026
Profit Margin
4.19%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Beta
0.3240x
vs all stocks
Updated Sep 20, 2026
52-Week Change
-8.84%
vs all stocks
Updated Sep 20, 2026
Market Capitalization
3.64BCNY
543.56M · vs all stocks (USD)
Updated Sep 20, 2026
Enterprise Value
2.69BCNY
401.90M · vs all stocks (USD)
Updated Sep 20, 2026
Trailing P/E
55.82x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Forward P/E
8.11x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Price to Sales (TTM)
2.23x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Price to Book (MRQ)
1.21x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Enterprise to Revenue
1.65x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Enterprise to EBITDA
18.68x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 21.94×.Updated Sep 20, 2026
Gross Margin
32.99%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Profit Margin
4.19%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Operating Margin
0.76%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Return on Assets (TTM)
-0.10%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Return on Equity (TTM)
2.27%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Revenue (TTM)
1.63BCNY
243.37M · vs all stocks (USD)
Updated Sep 20, 2026
Revenue per Share (TTM)
4.13CNYUpdated Sep 20, 2026
Quarterly Revenue Growth
24.80%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Gross Profit (TTM)
540.59MCNY
80.67M · vs all stocks (USD)
Updated Sep 20, 2026
EBITDA (TTM)
122.76MCNY
18.32M · vs all stocks (USD)
Updated Sep 20, 2026
Net Income (TTM)
68.32MCNY
10.19M · vs all stocks (USD)
Updated Sep 20, 2026
Quarterly Earnings Growth (YoY)
6.60%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Operating Cash Flow (TTM)
232.91MCNY
34.75M · vs all stocks (USD)
Updated Sep 20, 2026
Levered Free Cash Flow (TTM)
-11.55MCNY
-1.72M · vs all stocks (USD)
Updated Sep 20, 2026
Trailing Annual Dividend Rate
0.0330CNYUpdated Sep 20, 2026
Trailing Annual Dividend Yield
0.35%
vs all stocks
Updated Sep 20, 2026
5-Year Average Dividend Yield
1.04%
vs all stocks
Updated Sep 20, 2026
Payout Ratio
19.05%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Minority Interest (Equity)
-6.58MCNYFY2025 · Dec 31, 2025
Revenue
1.54BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
972.74MCNYFY2025 · Dec 31, 2025
Gross Profit
566.42MCNYFY2025 · Dec 31, 2025
Operating Income
61.40MCNY
9.16M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
46.09MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-15.27MCNYFY2025 · Dec 31, 2025
Net Income
61.36MCNYFY2025 · Dec 31, 2025
EBIT
48.66MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
259.12MCNYFY2025 · Dec 31, 2025
Research & Development
127.20MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
146.68MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
19.08MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.88MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
2.57MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.1600CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.1600CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
395.01MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
395.01MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
61.36MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
1.84MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
15.84MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-170.38MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
657.44MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
61.36MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
15.76MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-64.04MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
2.76MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-186.22MCNYFY2025 · Dec 31, 2025
Net Acquisitions
363.08KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-1.07BCNYFY2025 · Dec 31, 2025
Sale of Investments
994.50MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-258.35MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
34.84MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-45.00MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-51.99MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-14.56MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-76.71MCNYFY2025 · Dec 31, 2025
Shares Outstanding
384.32MSharesUpdated Sep 20, 2026
Float Shares
202.63MSharesUpdated Sep 20, 2026
% Held by Insiders
49.18%
vs all stocks
Updated Sep 20, 2026
% Held by Institutions
0.90%
vs all stocks
Updated Sep 20, 2026
Total Cash (MRQ)
1.04BCNY
155.55M · vs all stocks (USD)
Updated Sep 20, 2026
Total Cash per Share (MRQ)
2.71CNYUpdated Sep 20, 2026
Total Debt (MRQ)
94.58MCNY
14.11M · vs all stocks (USD)
Updated Sep 20, 2026
Total Debt to Equity (MRQ)
0.0316x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Current Ratio (MRQ)
3.10x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Book Value per Share (MRQ)
7.82CNYUpdated Sep 20, 2026
Total Assets
3.65BCNY
545.20M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.89BCNYFY2025 · Dec 31, 2025
Total Liabilities
706.06MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
1.76BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
82.08MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
623.99MCNYFY2025 · Dec 31, 2025
Cash
657.57MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
657.57MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
265.43MCNYFY2025 · Dec 31, 2025
Accounts Receivable
581.39MCNYFY2025 · Dec 31, 2025
Inventory
231.07MCNYFY2025 · Dec 31, 2025
Accounts Payable
356.41MCNYFY2025 · Dec 31, 2025
Short-term Debt
31.48MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
10.50MCNYFY2025 · Dec 31, 2025
Long-term Debt
27.74MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
1.37MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
384.32MCNYFY2025 · Dec 31, 2025
Retained Earnings
1.34BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.95BCNY
439.85M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
2.91MCNYFY2025 · Dec 31, 2025
52-Week Low
7.83CNYUpdated Sep 20, 2026
52-Week High
11.11CNYUpdated Sep 20, 2026
52-Week Change
-8.84%
vs all stocks
Updated Sep 20, 2026
Beta
0.3240x
vs all stocks
Updated Sep 20, 2026
50-Day MA
9.07CNYUpdated Sep 20, 2026
200-Day MA
9.57CNYUpdated Sep 20, 2026
Avg 10-Day Volume
3.41MSharesUpdated Sep 20, 2026
Avg 30-Day Volume
3.73MSharesUpdated Sep 20, 2026
Diluted EPS (TTM)
0.1700CNYUpdated Sep 20, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.